Eyeworld

INDICATIONS AND USAGE OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. IMPORTANT SAFETY INFORMATION OMIDRIA must be added to irrigating solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation. You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. Visit www.omidria.com OMEROS®, the OMEROS logo®, OMIDRIA®, the OMIDRIA logo®, and OMIDRIAssure® are registered trademarks of Omeros Corporation. © Omeros Corporation 2018, all rights reserved. 2018-013 THE POWER OF PREEMPTION OMIDRIA® is the first and only FDA-approved drug that provides continuous intracameral delivery of NSAID and mydriatic/anti-miotic therapy during cataract surgery 1 • Beginning October 1, 2018, OMIDRIA use in cataract and lens replacement surgery for patients with Medicare Part B coverage will be separately reimbursed for an additional 2 years Coming October 1, 2018—Reinstatement of separate payment under Medicare Part B extends the benefit of OMIDRIA to more patients. • Centers for Medicare & Medicaid Services (CMS) reimbursement will be managed under the same procedures that were in effect through 2017 • Omeros continues to support access to OMIDRIA through the OMIDRIAssure® Patient Assistance Program Omeros does not guarantee reimbursement by any third-party payer. To be eligible for the "Equal Access" Patient Assistance Program, patients must be enrolled in OMIDRIAssure prior to surgery. For any patient for whom your facility received a free vial through the "Equal Access" Patient Assistance Program, the patient's insurance carrier(s) should not be billed for OMIDRIA. OMIDRIAssure program services are subject to change without notice.

• Cover